ASCO 2017: Recurrence Score Results in High-Risk Patients With Renal Cell Carcinoma
In 2015, the 16-gene Recurrence Score was developed and validated to predict the risk of recurrence after nephrectomy in patients with stage I to III clear cell renal carcinoma. At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, Bernard J. Escudier, MD, of the Gustave Roussy Cancer Campus in Paris, France, and colleagues, presented further validation of Recurrence Score results in high-risk, stage III patients from the S-TRAC trial, in which adjuvant therapy with sunitinib prolonged disease-free survival in 615 patients with high-risk renal cell carcinoma (Abstract 4508).
Primary tissue from 212 patients with renal cell carcinoma was examined to further validate the Recurrence Score results in high-risk patients from S-TRAC. The Recurrence Score predicted time to recurrence and disease-free survival in both the sunitinib and placebo arms, with the strongest results observed in the placebo arm, where patients with high Recurrence Scores had a significantly higher risk.
These results demonstrate the prognostic accuracy of the Recurrence Score, which may be used to help identify high-risk patients who might benefit from adjuvant treatment. However, “the predictive value of the Recurrence Score to select patients for adjuvant sunitinib requires further investigation in independent adjuvant trials,” the investigators reported.